Pro-metastatic tumor–stroma interactions in breast cancer

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Weigelt B, Peterse JL, Van’T Veer LJ. Breast cancer metastasis: markers and models. Nat. Rev. Cancer5(8),591–602 (2005).
  Medline CASGoogle Scholar
• 2  Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev.8(2),98–101 (1989).▪▪ Based on the investigation of breast cancer autopsy reports, the author proposed the ‘seed and soil’ theory of tumor metastasis.
  Medline CASGoogle Scholar
• 3  Ewing J. Neoplastic Diseases: A Textbook on Tumors (4th Edition). WB Saunders, PA, USA (1928).
  Google Scholar
• 4  Sugarbaker EV. Cancer metastasis: a product of tumor–host interactions. Curr. Probl. Cancer3(7),1–59 (1979).
  Medline CASGoogle Scholar
• 5  Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet.25(1),30–38 (2009).
  Medline CASGoogle Scholar
• 6  Hu M, Polyak K. Molecular characterisation of the tumour microenvironment in breast cancer. Eur. J. Cancer44(18),2760–2765 (2008).
  Medline CASGoogle Scholar
• 7  De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int. J. Cancer123(10),2229–2238 (2008).
  Medline CASGoogle Scholar
• 8  Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure – an obstacle in cancer therapy. Nat. Rev. Cancer4(10),806–813 (2004).
  Medline CASGoogle Scholar
• 9  Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer2(3),161–174 (2002).
  Medline CASGoogle Scholar
• 10  Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer6(5),392–401 (2006).
  Medline CASGoogle Scholar
• 11  Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev. Cell18(6),884–901 (2010).▪▪ In-depth review of the complex interaction of cancer cells with their surroundings, both locally in the tumor organ and systemically in the whole body. The authors highlight the importance of such tissue organization in metastases, and also review microenvironments that confer promoting or inhibiting effects on cancer cells.
  Medline CASGoogle Scholar
• 12  Levental KR, Yu H, Kass L et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell139(5),891–906 (2009).
  Medline CASGoogle Scholar
• 13  Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ. Collagen reorganization at the tumor–stromal interface facilitates local invasion. BMC Med.4(1),38 (2006).
  MedlineGoogle Scholar
• 14  Bergamaschi A, Tagliabue E, Sorlie T et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J. Pathol.214(3),357–367 (2008).▪ Describes the classification of primary breast tumors on the basis of extracellular matrix composition and shows that such classification provides relevant information on the clinical outcome of breast carcinomas, further supporting the hypothesis that clinical outcome is strongly related to stromal characteristics.
  Medline CASGoogle Scholar
• 15  Casey T, Bond J, Tighe S et al. Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast Cancer Res. Treat.114(1),47–62 (2009).
  Medline CASGoogle Scholar
• 16  Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res.11(1),R7 (2009).
  MedlineGoogle Scholar
• 17  Kang Y, Siegel PM, Shu W et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell3(6),537–549 (2003).
  Medline CASGoogle Scholar
• 18  Minn AJ, Gupta GP, Siegel PM et al. Genes that mediate breast cancer metastasis to lung. Nature436(7050),518–524 (2005).
  Medline CASGoogle Scholar
• 19  Finak G, Bertos N, Pepin F et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med.14(5),518–527 (2008).
  Medline CASGoogle Scholar
• 20  Brouty-Boye D. Developmental biology of fibroblasts and neoplastic disease. Prog. Mol. Subcell Biol.40,55–77 (2005).
  Medline CASGoogle Scholar
• 21  Rasanen K, Vaheri A. Activation of fibroblasts in cancer stroma. Exp. Cell. Res.316(17),2713–2722 (2010).
  MedlineGoogle Scholar
• 22  Desmouliere A, Guyot C, Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int. J. Dev. Biol.48(5–6),509–517 (2004).
  Medline CASGoogle Scholar
• 23  Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am. J. Pathol.170(6),1807–1816 (2007).
  Medline CASGoogle Scholar
• 24  Mcanulty RJ. Fibroblasts and myofibroblasts: their source, function and role in disease. Int. J. Biochem. Cell. Biol.39(4),666–671 (2007).
  Medline CASGoogle Scholar
• 25  Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth – bystanders turning into key players. Curr. Opin. Genet. Dev.19(1),67–73 (2009).
  MedlineGoogle Scholar
• 26  Tsujino T, Seshimo I, Yamamoto H et al. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin. Cancer Res.13(7),2082–2090 (2007).
  Medline CASGoogle Scholar
• 27  Allinen M, Beroukhim R, Cai L et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell6(1),17–32 (2004).▪ A report of the gene expression profiles of different cell types within normal breast tissue and in situ and invasive breast carcinomas, revealing the importance of paracrine influence of myofibroblasts within the microenvironment.
  Medline CASGoogle Scholar
• 28  Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature454(7203),436–444 (2008).
  Medline CASGoogle Scholar
• 29  Lin EY, Gouon-Evans V, Nguyen AV, Pollard JW. The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J. Mammary Gland Biol. Neoplasia7(2),147–162 (2002).
  MedlineGoogle Scholar
• 30  Mantovani A, Allavena P, Sozzani S, Vecchi A, Locati M, Sica A. Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin. Cancer Biol.14(3),155–160 (2004).
  Medline CASGoogle Scholar
• 31  Andreu P, Johansson M, Affara NI et al. FcRγ activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell17(2),121–134 (2010).
  Medline CASGoogle Scholar
• 32  Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell4(6),431–436 (2003).
  Medline CASGoogle Scholar
• 33  Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer3(6),401–410 (2003).
  Medline CASGoogle Scholar
• 34  Lyden D, Hattori K, Dias S et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med.7(11),1194–1201 (2001).
  Medline CASGoogle Scholar
• 35  Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer8(8),618–631 (2008).
  Medline CASGoogle Scholar
• 36  Rajala MW, Scherer PE. Minireview: the adipocyte – at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology144(9),3765–3773 (2003).
  Medline CASGoogle Scholar
• 37  Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr. Rev.27(7),762–778 (2006).
  Medline CASGoogle Scholar
• 38  Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer4(8),579–591 (2004).
  Medline CASGoogle Scholar
• 39  Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res. Treat.111(2),329–342 (2008).
  MedlineGoogle Scholar
• 40  Dirat B, Bochet L, Escourrou G, Valet P, Muller C. Unraveling the obesity and breast cancer links: a role for cancer-associated adipocytes? Endocr. Dev.19,45–52 (2010).
  MedlineGoogle Scholar
• 41  Carmichael AR. Obesity and prognosis of breast cancer. Obesity Rev.7(4),333–340 (2006).
  CASGoogle Scholar
• 42  Dirat B, Bochet L, Dabek M et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res.71(7),2455–2465 (2011).
  Medline CASGoogle Scholar
• 43  Motrescu ER, Rio MC. Cancer cells, adipocytes and matrix metalloproteinase 11: a vicious tumor progression cycle. Biol. Chem.389(8),1037–1041 (2008).
  Medline CASGoogle Scholar
• 44  Cho JA, Park H, Lim EH, Lee KW. Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. Int. J. Oncol.40(1),130–138 (2012).▪ Suggests that tumor-derived exosomes can contribute to progression of tumor cells by converting adipose tissue-derived mesenchymal stem cells within tumor stroma into tumor-associated myofibroblasts, further demonstrating the importance of adipose tissue in tumor progression.
  Medline CASGoogle Scholar
• 45  Langley RR, Fidler IJ. Tumor cell–organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr. Rev.28(3),297–321 (2007).
  Medline CASGoogle Scholar
• 46  Micke P, Ostman A. Tumour–stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer45(Suppl. 2),S163–S175 (2004).
  MedlineGoogle Scholar
• 47  Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle5(15),1597–1601 (2006).
  Medline CASGoogle Scholar
• 48  Gaggioli C, Hooper S, Hidalgo-Carcedo C et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell. Biol.9(12),1392–1400 (2007).
  Medline CASGoogle Scholar
• 49  Chiquet M, Gelman L, Lutz R, Maier S. From mechanotransduction to extracellular matrix gene expression in fibroblasts. Biochim. Biophys. Acta1793(5),911–920 (2009).
  Medline CASGoogle Scholar
• 50  Kumar S, Weaver VM. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev.28(1–2),113–127 (2009).
  MedlineGoogle Scholar
• 51  Tschumperlin DJ, Dai G, Maly IV et al. Mechanotransduction through growth-factor shedding into the extracellular space. Nature429(6987),83–86 (2004).
  Medline CASGoogle Scholar
• 52  De Wever O, Nguyen QD, Van Hoorde L et al. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J.18(9),1016–1018 (2004).
  Medline CASGoogle Scholar
• 53  Olsen CJ, Moreira J, Lukanidin EM, Ambartsumian NS. Human mammary fibroblasts stimulate invasion of breast cancer cells in a three-dimensional culture and increase stroma development in mouse xenografts. BMC Cancer10,444 (2010).
  MedlineGoogle Scholar
• 54  Shimoda M, Mellody KT, Orimo A. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin. Cell Dev. Biol.21(1),19–25 (2010).
  Medline CASGoogle Scholar
• 55  Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Salmas M, Malamou-Mitsi V. A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int.95(4),655–659 (2005).
  MedlineGoogle Scholar
• 56  Ioachim E, Charchanti A, Briasoulis E et al. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur. J. Cancer38(18),2362–2370 (2002).▪ Prognostic value of selected extracellular matrix proteins within the tumor stroma is demonstrated in this clinical analysis.
  Medline CASGoogle Scholar
• 57  Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev.28(1–2),151–166 (2009).
  Medline CASGoogle Scholar
• 58  Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell. Biol.139(7),1861–1872 (1997).
  Medline CASGoogle Scholar
• 59  Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, Van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell66(1),107–119 (1991).
  Medline CASGoogle Scholar
• 60  Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature392(6672),190–193 (1998).
  Medline CASGoogle Scholar
• 61  Yoshida R, Kimura N, Harada Y, Ohuchi N. The loss of E-cadherin, α- and β-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int. J. Oncol.18(3),513–520 (2001).
  Medline CASGoogle Scholar
• 62  Borley AC, Hiscox S, Gee J et al. Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells. Breast Cancer Res.10(6),R103 (2008).▪ Recent data have suggested an intriguing link between E-cadherin and endocrine response in breast cancer, where low or absent E-cadherin expression in ER+, ductal breast cancers receiving tamoxifen appears to predict for poor survival.
  MedlineGoogle Scholar
• 63  Hiscox S, Rakha E, Smith C et al. Loss of E-cadherin expression in clinical breast cancer is associated with an adverse outcome on tamoxifen. Cancer Res.71(24), Supplement 3 (2011).
  Google Scholar
• 64  Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol.5(10),816–826 (2004).
  Medline CASGoogle Scholar
• 65  Aplin AE, Howe AK, Juliano RL. Cell adhesion molecules, signal transduction and cell growth. Curr. Opin. Cell Biol.11(6),737–744 (1999).
  Medline CASGoogle Scholar
• 66  Erler JT, Weaver VM. Three-dimensional context regulation of metastasis. Clin. Exp. Metastasis26(1),35–49 (2009).
  MedlineGoogle Scholar
• 67  Gimond C, Van Der Flier A, Van Delft S et al. Induction of cell scattering by expression of β1 integrins in β1-deficient epithelial cells requires activation of members of the ρ family of GTPases and downregulation of cadherin and catenin function. J. Cell Biol.147(6),1325–1340 (1999).
  Medline CASGoogle Scholar
• 68  De Jong JS, Van Diest PJ, Van Der Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: correlations with proliferation and angiogenesis. J. Pathol.184(1),53–57 (1998).
  Medline CASGoogle Scholar
• 69  Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J. Clin. Oncol.25(13),1637–1638 (2007).
  Medline CASGoogle Scholar
• 70  Hariharan S, Gustafson D, Holden S et al. Assessment of the biological and pharmacological effects of the α_n β₃ and α_n β₅ integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann. Oncol.18(8),1400–1407 (2007).
  Medline CASGoogle Scholar
• 71  Cabodi S, Di Stefano P, Leal Mdel P et al. Integrins and signal transduction. Adv. Exp. Med. Biol.674,43–54 (2010).
  Medline CASGoogle Scholar
• 72  Ilic D, Furuta Y, Kanazawa S et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature377(6549),539–544 (1995).
  Medline CASGoogle Scholar
• 73  Gabarra-Niecko V, Schaller MD, Dunty JM. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev.22(4),359–374 (2003).
  Medline CASGoogle Scholar
• 74  Parsons JT, Slack-Davis J, Tilghman R, Roberts WG. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin. Cancer Res.14(3),627–632 (2008).
  Medline CASGoogle Scholar
• 75  Kim TH, Kim HI, Soung YH, Shaw LA, Chung J. Integrin (α₆β₄) signals through Src to increase expression of S100A4, a metastasis-promoting factor: implications for cancer cell invasion. Mol. Cancer Res.7(10),1605–1612 (2009).
  Medline CASGoogle Scholar
• 76  Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev.22(4),337–358 (2003).
  Medline CASGoogle Scholar
• 77  Hiscox S, Jordan NJ, Morgan L, Green TP, Nicholson RI. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin. Exp. Metastasis24(3),157–167 (2007).
  Medline CASGoogle Scholar
• 78  Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen BR. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J. Clin. Endocrinol. Metab.94(6),2199–2203 (2009).
  Medline CASGoogle Scholar
• 79  Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res. Treat.97(3),263–274 (2006).
  Medline CASGoogle Scholar
• 80  Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J.278(1),28–45 (2011).
  Medline CASGoogle Scholar
• 81  Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J.278(1),16–27 (2011).
  Medline CASGoogle Scholar
• 82  Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem. Biol.3(11),895–904 (1996).
  Medline CASGoogle Scholar
• 83  Basset P, Bellocq JP, Wolf C et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature348(6303),699–704 (1990).
  Medline CASGoogle Scholar
• 84  Zhao YG, Xiao AZ, Park HI et al. Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: a putative role in the initiation of breast cancer invasion. Cancer Res.64(2),590–598 (2004).
  Medline CASGoogle Scholar
• 85  Lebeau A, Nerlich AG, Sauer U, Lichtinghagen R, Lohrs U. Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas. Anticancer Res.19(5B),4257–4264 (1999).
  Medline CASGoogle Scholar
• 86  Wiechmann L, Kuerer HM. The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer112(10),2130–2142 (2008).
  MedlineGoogle Scholar
• 87  Cichon MA, Degnim AC, Visscher DW, Radisky DC. Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer. J. Mammary Gland. Biol. Neoplasia15(4),389–397 (2010).
  MedlineGoogle Scholar
• 88  Schuetz CS, Bonin M, Clare SE et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res.66(10),5278–5286 (2006).
  Medline CASGoogle Scholar
• 89  Borrello MG, Alberti L, Fischer A et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc. Natl Acad. Sci. USA102(41),14825–14830 (2005).
  Medline CASGoogle Scholar
• 90  Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat. Med.13(10),1211–1218 (2007).
  Medline CASGoogle Scholar
• 91  Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell6(5),447–458 (2004).
  Medline CASGoogle Scholar
• 92  Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis30(7),1073–1081 (2009).
  Medline CASGoogle Scholar
• 93  Harmey JH, Dimitriadis E, Kay E, Redmond HP, Bouchier-Hayes D. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor β-1. Ann. Surg. Oncol.5(3),271–278 (1998).
  Medline CASGoogle Scholar
• 94  Doedens AL, Stockmann C, Rubinstein MP et al. Macrophage expression of hypoxia-inducible factor-1 α suppresses T-cell function and promotes tumor progression. Cancer Res.70(19),7465–7475 (2010).
  Medline CASGoogle Scholar
• 95  Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J. Leukoc. Biol.84(3),623–630 (2008).
  Medline CASGoogle Scholar
• 96  Coussens LM, Werb Z. Inflammation and cancer. Nature420(6917),860–867 (2002).
  Medline CASGoogle Scholar
• 97  Leek RD, Talks KL, Pezzella F et al. Relation of hypoxia-inducible factor-2 α (HIF-2 α) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res.62(5),1326–1329 (2002).
  Medline CASGoogle Scholar
• 98  Luo Y, Zhou H, Krueger J et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest.116(8),2132–2141 (2006).
  Medline CASGoogle Scholar
• 99  Byzova TV, Goldman CK, Pampori N et al. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol. Cell6(4),851–860 (2000).
  Medline CASGoogle Scholar
• 100  Klein S, Bikfalvi A, Birkenmeier TM, Giancotti FG, Rifkin DB. Integrin regulation by endogenous expression of 18-kDa fibroblast growth factor-2. J. Biol. Chem.271(37),22583–22590 (1996).
  Medline CASGoogle Scholar
• 101  Fernandez-Sauze S, Grall D, Cseh B, Van Obberghen-Schilling E. Regulation of fibronectin matrix assembly and capillary morphogenesis in endothelial cells by Rho family GTPases. Exp. Cell Res.315(12),2092–2104 (2009).
  Medline CASGoogle Scholar
• 102  Jin H, Aiyer A, Su J et al. A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. J. Clin. Invest.116(3),652–662 (2006).
  Medline CASGoogle Scholar
• 103  Stacker SA, Caesar C, Baldwin ME et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med.7(2),186–191 (2001).
  Medline CASGoogle Scholar
• 104  Van Zijl F, Mair M, Csiszar A et al. Hepatic tumor–stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene28(45),4022–4033 (2009).
  Medline CASGoogle Scholar
• 105  Orimo A, Gupta PB, Sgroi DC et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell121(3),335–348 (2005).
  Medline CASGoogle Scholar
• 106  Ao M, Williams K, Bhowmick NA, Hayward SW. Transforming growth factor-β promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res.66(16),8007–8016 (2006).
  Medline CASGoogle Scholar
• 107  Bhowmick NA, Chytil A, Plieth D et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science303(5659),848–851 (2004).
  Medline CASGoogle Scholar
• 108  Niu YN, Xia SJ. Stroma–epithelium crosstalk in prostate cancer. Asian J. Androl.11(1),28–35 (2009).
  Medline CASGoogle Scholar
• 109  Hernandez L, Smirnova T, Kedrin D et al. The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin β1 and CXCL12. Cancer Res.69(7),3221–3227 (2009).
  Medline CASGoogle Scholar
• 110  Potter SM, Dwyer RM, Hartmann MC et al. Influence of stromal-epithelial interactions on breast cancer in vitro and in vivo . Breast Cancer Res. Treat.131(2),401–411 (2012).
  Medline CASGoogle Scholar
• 111  Paulsson J, Sjoblom T, Micke P et al. Prognostic significance of stromal platelet-derived growth factor β-receptor expression in human breast cancer. Am. J. Pathol.175(1),334–341 (2009).
  MedlineGoogle Scholar
• 112  Witkiewicz AK, Dasgupta A, Sotgia F et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am. J. Pathol.174(6),2023–2034 (2009).
  Medline CASGoogle Scholar
• 113  Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu. Rev. Pathol.7,423–467 (2012).
  Medline CASGoogle Scholar
• 114  Auvinen P, Tammi R, Parkkinen J et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am. J. Pathol.156(2),529–536 (2000).
  Medline CASGoogle Scholar
• 115  Kim MY, Oskarsson T, Acharyya S et al. Tumor self-seeding by circulating cancer cells. Cell139(7),1315–1326 (2009).
  MedlineGoogle Scholar
• 116  Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer9(4),274–284 (2009).
  Medline CASGoogle Scholar
• 117  Kaplan RN, Riba RD, Zacharoulis S et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature438(7069),820–827 (2005).
  Medline CASGoogle Scholar
• 118  Hiratsuka S, Nakamura K, Iwai S et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell2(4),289–300 (2002).
  Medline CASGoogle Scholar
• 119  Erler JT, Bennewith KL, Cox TR et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell15(1),35–44 (2009).
  Medline CASGoogle Scholar
• 120  Kim S, Takahashi H, Lin WW et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature457(7225),102–106 (2009).
  Medline CASGoogle Scholar
• 121  Meltzer A. Dormancy and breast cancer. J. Surg. Oncol.43(3),181–188 (1990).
  Medline CASGoogle Scholar
• 122  Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N. Engl. J. Med.328(17),1237–1243 (1993).
  Medline CASGoogle Scholar
• 123  Folkman J, Kalluri R. Cancer without disease. Nature427(6977),787 (2004).
  Medline CASGoogle Scholar
• 124  Allan AL, Vantyghem SA, Tuck AB, Chambers AF. Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Dis.26,87–98 (2006).
  Medline CASGoogle Scholar
• 125  Naumov GN, Macdonald IC, Weinmeister PM et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res.62(7),2162–2168 (2002).
  Medline CASGoogle Scholar
• 126  Naumov GN, Townson JL, Macdonald IC et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res. Treat.82(3),199–206 (2003).
  Medline CASGoogle Scholar
• 127  Marsden CG, Wright MJ, Pochampally R, Rowan BG. Breast tumor-initiating cells isolated from patient core biopsies for study of hormone action. Methods Mol. Biol. (Clifton, N. J.)590,363–375 (2009).
  MedlineGoogle Scholar
• 128  Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer3(12),895–902 (2003).
  Medline CASGoogle Scholar
• 129  Millerot-Serrurot E, Guilbert M, Fourre N et al. 3D collagen type I matrix inhibits the antimigratory effect of doxorubicin. Cancer Cell Int.10,26 (2010).▪▪ These data highlight the importance of the 3D matrix configuration on tumor cell response to anti-invasive drugs. This article supports the use of appropriate in vitro models that more closely reflect the tumor microenvironment to determine the response of chemotherapeutic agents.
  MedlineGoogle Scholar
• 130  Sethi T, Rintoul RC, Moore SM et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med.5(6),662–668 (1999).
  Medline CASGoogle Scholar
• 131  Fridman R, Giaccone G, Kanemoto T, Martin GR, Gazdar AF, Mulshine JL. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc. Natl Acad. Sci. USA87(17),6698–6702 (1990).
  Medline CASGoogle Scholar
• 132  Berube M, Talbot M, Collin C et al. Role of the extracellular matrix proteins in the resistance of SP6.5 uveal melanoma cells toward cisplatin. Int. J. Oncol.26(2),405–413 (2005).
  Medline CASGoogle Scholar
• 133  Hiscox S, Barrett-Lee P, Nicholson RI. Therapeutic targeting of tumor–stroma interactions. Expert Opin. Ther. Targets15(5),609–621 (2011).▪▪ Highlights the molecular elements in the tumor stroma that might represent novel therapeutic targets.
  Medline CASGoogle Scholar
• 134  Stupp R, Hegi ME, Neyns B et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol.28(16),2712–2718 (2010).
  Medline CASGoogle Scholar
• 135  Nam JM, Chung Y, Hsu HC, Park CC. β1 integrin targeting to enhance radiation therapy. Int. J. Radiat. Biol.85(11),923–928 (2009).
  Medline CASGoogle Scholar
• 136  Kim TJ, Landen CN, Lin YG et al. Combined anti-angiogenic therapy against VEGF and integrin αVβ3 in an orthotopic model of ovarian cancer. Cancer Biol. Ther.8(23),2263–2272 (2009).
  MedlineGoogle Scholar
• 137  Hehlgans S, Lange I, Eke I, Cordes N. 3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226. Radiother. Oncol.92(3),371–378 (2009).
  Medline CASGoogle Scholar
• 138  Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest.116(7),1955–1962 (2006).
  Medline CASGoogle Scholar